Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-04-24 Report Publication Anno…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic - 2024 04 23 Press Release (EN)_AnnualReportPostpone_Final.pdf
Report Publication Announcement Classification · 100% confidence The document is explicitly titled as a "PRESS RELEASE" dated 24/04/2024. The core content announces the postponement of two key events: the publication of the '2023 annual report' and the 'annual general meeting of shareholders'. It also provides temporary, non-audited financial figures for 2023. Since the document is an announcement *about* the postponement of the Annual Report (10-K) and the AGM, and it is structured as a press release providing key updates rather than the full, detailed report itself, it fits best under the category of an Earnings Release (ER) or potentially a Regulatory Filing (RNS) if it were purely administrative. However, because it contains key financial highlights (operating income, operating loss, cash position) for the period, it strongly aligns with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). The postponement of the AGM and the Annual Report publication are secondary announcements within this primary financial update context. It is not the full 10-K, nor is it solely an AGM presentation (AGM-R).
2024-04-24 English
BioSenic - 2024 04 23 Press Release (FR)_AnnualReportPostpone_Final.pdf
Earnings Release Classification · 95% confidence The document is a press release titled "BioSenic reporte son assemblée générale annuelle des actionnaires et fournit des chiffres financiers temporaires non-audités pour 2023" (BioSenic reports its annual general meeting of shareholders and provides unaudited temporary financial figures for 2023). The text explicitly states that the publication of the 2023 annual report and the AGM are postponed. It provides key unaudited financial highlights for 2023 (operating result, operating loss, cash position). This content structure—announcing key financial metrics for a period without being the full, audited report itself, and often accompanying a delay or scheduling change for formal meetings/reports—is characteristic of an Earnings Release (ER). While it mentions the AGM and Annual Report, the document itself is the announcement containing preliminary results, not the formal 10-K or the AGM materials (AGM-R). It is too detailed for a simple Report Publication Announcement (RPA) as it contains substantive financial data, making ER the best fit. FY 2023
2024-04-24 French
BIOS_PR_2024-04-17 Final Transparency Notification_EN_Final.pdf
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "PRESS RELEASE – REGULATED INFORMATION" and details transparency notifications received regarding changes in shareholdings by an individual (François Rieger) crossing a specific threshold (10%). This content directly relates to insider transactions or major shareholder changes, which falls under the category of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the core subject is the notification of a change in voting rights/shareholding percentage by a person subject to notification requirements, 'Major Shareholding Notification' (MRQ) is the most precise fit, as it deals with crossing ownership thresholds. The document structure (press release format) suggests it is an official disclosure of this event.
2024-04-18 English
BIOS_PR_2024-04-17 Final Transparency Notification_FR_FINAL.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) and announces the receipt of transparency notifications from an individual shareholder, François Rieger, regarding a change in his shareholding percentage (crossing the 10% passive threshold). This type of filing, which reports personal share transactions by executives or major shareholders crossing specific ownership thresholds, directly corresponds to the definition of Director's Dealing or Major Shareholding Notification. Since the content explicitly details the notification of a change in significant share ownership (crossing the 10% threshold), the most appropriate classification is Major Shareholding Notification (MRQ). It is not a Director's Dealing (DIRS) as the individual is identified as a major shareholder whose position changed, not necessarily an executive reporting a personal trade, although there is overlap. MRQ is more precise for threshold crossing notifications.
2024-04-18 French
BioSenic - complément Press Release (EN) - plan de restructuration - final(1300914.1).PDF
Capital/Financing Update Classification · 99% confidence The document is dated April 12, 2024, and is titled "BioSenic provides further information on its restructuring plan." It details the potential impact of a global restructuring plan on the company's debt position, including a detailed table of debt components and conversion terms for convertible bonds. It also explicitly states it is a "PRESS RELEASE - PRIVILEGED INFORMATION 12/04/2024." This content—providing specific financial details and updates related to a major corporate action (restructuring/financing) via a press release—most closely aligns with a Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) focusing on operational results, or a simple Dividend Notice (DIV). Since it details financing activities and debt structure changes related to a restructuring plan, CAP is the most appropriate classification.
2024-04-12 English
BioSenic - complément Press Release (FR) - plan de restructuration - final(1300915.1).PDF
Capital/Financing Update Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE" (Press Release – Privileged Information) dated 12/04/2024. It provides supplementary information regarding a previously announced global restructuring plan, detailing the current debt situation with a specific table showing debt breakdown and potential impact, and directs readers to the company website for conversion terms for bondholders. This is a specific corporate announcement concerning financial restructuring and debt obligations, issued via a press release format. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). Since it details significant financial restructuring and debt implications, it most closely aligns with a Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the focus on debt restructuring and financing terms, 'CAP' is the most specific fit, although 'RNS' is a strong secondary candidate if 'CAP' were too narrow. However, the content is fundamentally about capital structure changes resulting from the restructuring plan. The document is not merely announcing a report's publication (RPA).
2024-04-12 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.